This paper is in the following e-collection/theme issue:

Cyberpharmacies (56) Medicine 2.0: Social Media, Open, Participatory, Collaborative Medicine (1800) Crowdsourcing and Mechanical Turks (101)

Published on in Vol 15, No 8 (2013): August

Crowdsourcing Black Market Prices For Prescription Opioids

Crowdsourcing Black Market Prices For Prescription Opioids

Crowdsourcing Black Market Prices For Prescription Opioids

Authors of this article:

Nabarun Dasgupta1 ;   Clark Freifeld1, 2 ;   John S Brownstein1, 2, 3 ;   Christopher Mark Menone1 ;   Hilary L Surratt4 ;   Luke Poppish5 ;   Jody L Green5 ;   Eric J Lavonas5 ;   Richard C Dart5, 6
Article Authors Cited by (61) Tweetations (42) Metrics

Journals

  1. Katsuki T, Mackey T, Cuomo R. Establishing a Link Between Prescription Drug Abuse and Illicit Online Pharmacies: Analysis of Twitter Data. Journal of Medical Internet Research 2015;17(12):e280 View
  2. Créquit P, Mansouri G, Benchoufi M, Vivot A, Ravaud P. Mapping of Crowdsourcing in Health: Systematic Review. Journal of Medical Internet Research 2018;20(5):e187 View
  3. Schwab-Reese L, Hovdestad W, Tonmyr L, Fluke J. The potential use of social media and other internet-related data and communications for child maltreatment surveillance and epidemiological research: Scoping review and recommendations. Child Abuse & Neglect 2018;85:187 View
  4. Berger R. Buprenorphine for opioid dependence. Mental Health Clinician 2013;3(6):286 View
  5. Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: Comparison with heroin and morphine. British Journal of Pharmacology 2020;177(2):254 View
  6. Bodnar R. Endogenous opiates and behavior: 2013. Peptides 2014;62:67 View
  7. Homer J, Wakeland W. A dynamic model of the opioid drug epidemic with implications for policy. The American Journal of Drug and Alcohol Abuse 2021;47(1):5 View
  8. Iwanicki J, Severtson S, McDaniel H, Rosenblum A, Fong C, Cicero T, Ellis M, Kurtz S, Buttram M, Dart R, Landau R. Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States. PLOS ONE 2016;11(12):e0167499 View
  9. Pashmineh Azar A, Cruz‐Mullane A, Podd J, Lam W, Kaleem S, Lockard L, Mandel M, Chung D, Simoyan O, Davis C, Nichols S, McCall K, Piper B. Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidemiology and Drug Safety 2020;29(6):708 View
  10. Minhas M, Leri F. A Multifaceted Analysis of Oxycodone Addiction. International Journal of Mental Health and Addiction 2018;16(4):1016 View
  11. Wiegand T, Le Lait M, Bartelson B, Dart R, Green J. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System. The Journal of Pain 2016;17(6):745 View
  12. Lebin J, Murphy D, Severtson S, Bau G, Dasgupta N, Dart R. Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphone. Pharmacoepidemiology and Drug Safety 2019;28(1):25 View
  13. Fan M, Tscheng D, Hamilton M, Trbovich P. Opioid losses in terms of dosage and value, January 2012 to September 2017: a retrospective analysis of Health Canada data. CMAJ Open 2020;8(1):E113 View
  14. Weiner M. The Potential of Crowdsourcing to Improve Patient-Centered Care. The Patient - Patient-Centered Outcomes Research 2014;7(2):123 View
  15. Horyniak D, Agius P, Degenhardt L, Reddel S, Higgs P, Aitken C, Stoové M, Dietze P. Patterns of, and Factors Associated With, Illicit Pharmaceutical Opioid Analgesic Use in a Prospective Cohort of People Who Inject Drugs in Melbourne, Australia. Substance Use & Misuse 2015;50(13):1650 View
  16. DePriest A, Heltsley R, Black D, Mitchell J, LoDico C, Flegel R, Cone E. Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration. Journal of Analytical Toxicology 2016;40(8):566 View
  17. Hulme S, Bright D, Nielsen S. The source and diversion of pharmaceutical drugs for non-medical use: A systematic review and meta-analysis. Drug and Alcohol Dependence 2018;186:242 View
  18. Dart R, Surratt H, Le Lait M, Stivers Y, Bebarta V, Freifeld C, Brownstein J, Burke J, Kurtz S, Dasgupta N. Diversion and Illicit Sale of Extended Release Tapentadol in the United States. Pain Medicine 2016;17(8):1490 View
  19. Vosburg S, Severtson S, Dart R, Cicero T, Kurtz S, Parrino M, Green J. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System. The Journal of Pain 2018;19(4):439 View
  20. Barratt M, Ferris J, Winstock A. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. Addiction 2014;109(5):774 View
  21. Brady C, Villanti A, Pearson J, Kirchner T, Gupta O, Shah C. Rapid Grading of Fundus Photographs for Diabetic Retinopathy Using Crowdsourcing. Journal of Medical Internet Research 2014;16(10):e233 View
  22. Hswen Y, Zhang A, Brownstein J. Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010–2018. Preventive Medicine 2020;137:106105 View
  23. Wazny K. Applications of crowdsourcing in health: an overview. Journal of Global Health 2018;8(1) View
  24. Oesterle T, Thusius N, Rummans T, Gold M. Medication-Assisted Treatment for Opioid-Use Disorder. Mayo Clinic Proceedings 2019;94(10):2072 View
  25. Corazza O, Valeriani G, Bersani F, Corkery J, Martinotti G, Bersani G, Schifano F. “Spice,” “Kryptonite,” “Black Mamba”: An Overview of Brand Names and Marketing Strategies of Novel Psychoactive Substances on the Web. Journal of Psychoactive Drugs 2014;46(4):287 View
  26. Kazemi D, Borsari B, Levine M, Dooley B. Systematic review of surveillance by social media platforms for illicit drug use. Journal of Public Health 2017;39(4):763 View
  27. Simpson K, Moran M, McCall K, Herbert J, Foster M, Simoyan O, Shah D, Desrosiers C, Nichols S, Piper B. Increasing heroin, cocaine, and buprenorphine arrests reported to the Maine Diversion Alert Program. Forensic Science International 2019;303:109924 View
  28. Schmidt T, Haddox J, Nielsen A, Wakeland W, Fitzgerald J. Key Data Gaps Regarding the Public Health Issues Associated with Opioid Analgesics. The Journal of Behavioral Health Services & Research 2015;42(4):540 View
  29. Brown R, Riley M, Ulrich L, Kraly E, Jenkins P, Krupa N, Gadomski A. Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity. Drug and Alcohol Dependence 2017;178:348 View
  30. Van Hout M, Bingham T. Responsible vendors, intelligent consumers: Silk Road, the online revolution in drug trading. International Journal of Drug Policy 2014;25(2):183 View
  31. Cummings O, Morris A, Enders J, McIntire G. Normalizing Oral Fluid Hydrocodone Data Using Calculated Blood Volume. Journal of Analytical Toxicology 2016;40(7):486 View
  32. Li J, Xu Q, Shah N, Mackey T. A Machine Learning Approach for the Detection and Characterization of Illicit Drug Dealers on Instagram: Model Evaluation Study. Journal of Medical Internet Research 2019;21(6):e13803 View
  33. Kingsley S, Gray M, Suri S. Accounting for Market Frictions and Power Asymmetries in Online Labor Markets. Policy & Internet 2015;7(4):383 View
  34. Geoffrey Severtson S, Kreider S, Amioka E, Margolin Z, Iwanicki J, Dart R. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER. Pain Medicine 2020;21(12):3660 View
  35. Dave D, Deza M, Horn B. Prescription drug monitoring programs, opioid abuse, and crime. Southern Economic Journal 2021;87(3):808 View
  36. Li Z, Du X, Liao X, Jiang X, Champagne-Langabeer T. Demystifying the Dark Web Opioid Trade: Content Analysis on Anonymous Market Listings and Forum Posts. Journal of Medical Internet Research 2021;23(2):e24486 View
  37. Yanuck J, Lee J, Saadat S, Rouhi J, Ghanem G, Chakravarthy B, Shah S, Enax-Krumova E. Opioid Prescription Patterns for Discharged Patients from the Emergency Department. Pain Research and Management 2021;2021:1 View
  38. Connors N, Mazer-Amirshahi M, Motov S, Kim H. Relative Addictive Potential of Opioid Analgesic Agents. Pain Management 2021;11(2):201 View
  39. Babalonis S, Comer S, Jones J, Nuzzo P, Lofwall M, Manubay J, Hatton K, Whittington R, Walsh S. Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans — pilot study outcomes. Psychopharmacology 2021;238(9):2503 View
  40. Shah N, Li J, Mackey T. An Unsupervised Machine Learning Approach for the Detection and Characterization of Illicit Drug-Dealing Comments and Interactions on Instagram. Substance Abuse 2022;43(1):273 View
  41. Black J, Margolin Z, Bau G, Olson R, Iwanicki J, Dart R. Web-Based Discussion and Illicit Street Sales of Tapentadol and Oxycodone in Australia: Epidemiological Surveillance Study. JMIR Public Health and Surveillance 2021;7(12):e29187 View
  42. Mutter R, Black J, Iwanicki J. Changes in the Street Prices of Prescription Opioids During the COVID-19 Pandemic. Psychiatric Services 2023;74(1):63 View
  43. Scheibein F, Donnelly W, Wells J. Assessing open science and citizen science in addictions and substance use research: A scoping review. International Journal of Drug Policy 2022;100:103505 View
  44. Hu C, Liu B, Ye Y, Li X. Fine-grained classification of drug trafficking based on Instagram hashtags. Decision Support Systems 2023;165:113896 View
  45. Kaufman D, Kennalley A, McCall K, Piper B. Examination of methadone involved overdoses during the COVID-19 pandemic. Forensic Science International 2023;344:111579 View
  46. Hayes C, Goree J, Turpin J, Ortiz H, Smith G, Gokarakonda S, Hyde C, Cucciare M. Leveraging the Prescription Drug Monitoring Program to Curb Opioid Prescribing in Arkansas. Journal of Prevention 2022;43(3):337 View
  47. Haupt M, Cuomo R, Li J, Nali M, Mackey T. The influence of social media affordances on drug dealer posting behavior across multiple social networking sites (SNS). Computers in Human Behavior Reports 2022;8:100235 View
  48. Roe S, DeSalve D, Piper B. Analyzing Black Market Sales of the Second-Line ADHD Medication Atomoxetine. Pharmacoepidemiology 2023;2(4):320 View
  49. Pande L, Arnet R, Piper B. An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine. Pharmaceuticals 2023;16(10):1397 View
  50. Wagner K, Fiuty P, Page K, Tracy E, Nocera M, Miller C, Tarhuni L, Dasgupta N. Prevalence of fentanyl in methamphetamine and cocaine samples collected by community-based drug checking services. Drug and Alcohol Dependence 2023;252:110985 View
  51. Sudan H, Tai A, Kim J, Krausz R. Decrypting the cryptomarkets: Trends over a decade of the Dark Web drug trade. Drug Science, Policy and Law 2023;9 View
  52. Washington P. A Perspective on Crowdsourcing and Human-in-the-Loop Workflows in Precision Health. Journal of Medical Internet Research 2024;26:e51138 View
  53. Soliman A. Disrupting Drug Markets: The Effects of Crackdowns on Rogue Opioid Suppliers. SSRN Electronic Journal 2023 View
  54. Fipps D, Oesterle T, Kolla B. Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder. Seminars in Neurology 2024;44(04):441 View
  55. Yang J, Mishra A. Diversion in Prescription Opioid Supply Chains: Evidence from the Drug Supply Chain Security Act. SSRN Electronic Journal 2023 View
  56. Yang J, Mishra A. Diversion in Prescription Opioid Supply Chains: Evidence from the Drug Supply Chain Security Act. Manufacturing & Service Operations Management 2025;27(3):679 View
  57. Shen Y, Jiang D, Andritsos D, Li X. Spillover Effects From Health Information Systems Integration: Evidence From Prescription Drug Monitoring Programs. Journal of Operations Management 2025 View

Books/Policy Documents

  1. Sevigny E, Fuleihan B. The Handbook of Drugs and Society. View
  2. Cao M, Zhang J, Xu S, Ying Z. Cloud Computing. View
  3. Jordan A, Martinez C, Isom J. Treating Opioid Use Disorder in General Medical Settings. View
  4. Harinam V, Ariel B. Law Enforcement Strategies for Disrupting Cryptomarkets. View